Goldman Sachs has significantly upgraded BioNTech shares. As the legacy of COVID-19 vaccines fades into the background, the cancer research pipeline becomes the focus of assessment.
• Goldman Sachs upgrades BioNTech
• New price target implies strong upside potential
• Seven late-stage clinical data publications are expected in 2026
BioNTech’s strategic realignment: Beyond COVID-19
Goldman Sachs adjusted its valuation of BioNTech shares on Friday. The rating was raised from “Neutral” to “Buy” and the price target was increased from $115 to $142. The analysts base their optimistic assessment on BioNTech’s clear positioning in the field of next-generation oncology. The company is particularly focused on bispecific antibodies (such as BNT327) and antibody-drug conjugates (ADCs). According to the bank, these technologies have the potential to take the effectiveness of cancer therapies to a new level, after standard therapies such as PD-1 inhibitors in combination with chemotherapy were already established years ago.
With its broad portfolio, BioNTech is targeting a total market of over $100 billion. Despite existing competitive risks from other pharmaceutical giants, BioNTech offers a “unique risk-reward ratio,” according to Goldman Sachs. The company’s goal remains to mature into a multi-product oncology company with multiple marketing approvals by 2030.
BioNTech shares under the microscope: analyst consensus and market data
The general mood on Wall Street is currently very positive. According to current TipRanks data, the stock is rated a Strong Buy based on 12 Buy recommendations and 3 Hold recommendations, with no analysts recommending Sell. At $141.93, the average price target is almost identical to the new forecast from Goldman Sachs. Based on the NASDAQ closing price on Friday ($109, +2.76 percent), this results in a mathematical potential of around 30.2 potential.
Investors are now looking forward to March 10, when management will provide detailed figures for the past fiscal year and an updated outlook on research progress in 2026.
Editorial team finanzen.net
This text is for informational purposes only and does not constitute an investment recommendation. finanzen.net GmbH excludes any claims for recourse.
By the way: BioNTech (ADRs) and other US stocks can even be traded on finanzen.net ZERO until 11 p.m. (without order fees, plus spreads). Open a depot now for free and secure a new customer bonus!
Selected leverage products on BioNTech (ADRs)
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired leverage and we will show you suitable open-end products on BioNTech (ADRs)
The leverage must be between 2 and 20
Advertising
Image sources: Pavlo Gonchar/SOPA Images/LightRocket via Getty Images, Thomas Lohnes/Getty Images